QazCoVac-P

QazCoVac-P is a recombinant protein subunit vaccine developed by the Research Institute for Biological Safety Problems (RIBSP) in Kazakhstan for the prevention of COVID-19. It is distinct from the institute's first vaccine, QazVac, which is an inactivated virus vaccine. QazCoVac-P utilizes a purified recombinant protein, typically the SARS-CoV-2 spike protein or a specific fragment such as the receptor-binding domain (RBD), to act as an antigen that stimulates the host's immune system. By introducing only a specific viral protein rather than the whole virus, the vaccine is designed to elicit protective neutralizing antibodies and cellular immune responses with a favorable safety profile. The vaccine has been evaluated in Phase I and Phase II clinical trials in Kazakhstan to assess its safety, tolerability, and immunogenicity in healthy adult volunteers, including the elderly population.

Other names

QazCoVac-PCOVID-19 Subunit Vaccine (RIBSP)